Egis's nine-month sales growth in eastern Europe offsets losses in the west
This article was originally published in Scrip
Executive Summary
Exports from Egis, Hungary's second-largest pharmaceutical manufacturer, were flat at around $314 million in the first nine months of its financial year, which will end on 30 September. Their growth in central and eastern Europe offset their decline in western Europe and overseas.